In this Phase 3 trial of peanut OIT in children and adolescents who were highly allergic to peanut, treatment with AR101 resulted in higher doses of peanut protein that could be ingested without dose-limiting symptoms and in lower symptom severity during peanut exposure at the exit food challenge than placebo. Published in New Engl J Med, Nov 2018. See Life changing research at RMCH shown on the One Show.

WordPress Video Lightbox Plugin